INTRODUCTION
In 1995 the National Institute of Health (NIH) proposed a classification of the prostatitis now internationally accepted (1) . The overall incidence of prostatitis in Italy results to be about 13.8% (2) . Based on the literature available data, 5% of the prostatitis belongs the categories I and II. The antibiotics treatment, in general, results in a good response with resolution of symptoms. The majority of the prostatitis, however, is represented by the category III type. This is a therapeutic challenge for the practitioners. Following a first episode of prostatitis, the likelihood of subsequent episodes is very high, ranging from 20% to 50% in proportion to the age of the subject. Prior to establish a possible treatment protocol an accurate medical history and physical examination should be carried out. This obviously includes an accurate digital rectal examination. It is also mandatory to administer the NIH-CPSI and the International Prostate Symptom Score (I-PSS) questionnaires and to perform the Meares and Stamey test (3), uroflowmetry, urethral swap test, semen culture, total PSA and a transrectal ultrasonography. In spite of the fact that type III prostatitis is by definition non-bacterial, in many cases the antibiotics administration has resulted in a significant improvement of the symptoms. In fact, the literature supports the use of antibiotics in these cases (4, 5) . In both cases bacterial and non-bacterial prostatitis alfa blockers can be added to the antibiotics. Modern naturopathic doctors however believe that the prescription of antibiotics for chronic pelvic pain syndrome (CPPS) can do more harm than good when bacteria has not been identified. However, CPPS is linked to a high rate of treatment failure and patient's frustration due to their unclear etiology and complexity of symptoms. The primary objectives, addressing this condition, are the mitigation of the symptoms, the improvement of the quality of life, minimizing the side effects of the medical treatment.
Phytotherapeutic agents remains then a suitable choice, especially for their low or absent side effects. However, there are few prospective and controlled studies to support their use (6, 7) . Several studies demonstrated that a complex of flower pollen extract is able to produce a persistent improvement in symptoms of CPPS with a significant reduction of the NIH-CPSI index (8, 9). A phase II study by Cai et al. demonstrated that the flower pollen extract, in association with vitamins, improved significantly the symptoms, the pain, and the QoL score of patients with non-inflammatory Chronic Prostatitis (CP)/CPPS, without severe side effects (10). Additional studies have demonstrated that several other extract might be able to treat CP/CPPS. Bioflavonoids are a family of polyphenolic molecules, of which the quercetin is a representative. Quercetin has a theoretical benefits for patients with an ongoing inflammatory or ischemic process of the prostate, mechanisms, which are recognized to be the basis of CPPS. Furthermore, the usually suggested diet poor in bioflavonoids (green tea, caffeine, red wine), quercetin in particular, could worsen the symptoms of CP/CPPS (11) . The administration of bioflavonoids is then indicated in order to improve the quality of life of CP/CPPS patients. Also, the bioflavonoids have been shown to play a key role in the inhibition of prostatic cancer cells in vitro (19) . The objective of this study is to assess the efficacy and tolerability of the pollen extract compared to the quercetin in patients with CP/CPPS. The evaluation of the quality of life and the safety of the active principle represent the secondary endpoints of the study.
MATERIALS AND METHODS
We performed a non-sponsored phase I-II study in a single urological institution. The study was conducted according to Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. Before the beginning of the study, all participants signed a written informed consent. Between March 2016 to June 2016, all consecutive patients presenting with clinical diagnosis of CP/CPPS (classes IIIa or IIIb) were recruited in a single urological institution. The study was designed in accordance with the CP/CPPS clinical trial guidelines described by Chronic Prostatitis Collaborative Research Network NIH (12) . All the eligible patients completed and returned also the base questionnaires (IPSS, QoL, NIH-CPSI). Following the guidelines of the European Association of Urology (EAU) every patient underwent an thorough urological examination and Meares-Stamey test (13) . All the patients who qualified for the study were randomized to either receive flower pollen extract (DEPROX 500 ® mg 2 capsules once a day), or quercetin (500 mg twice a day) for 4 weeks. The use of bioflavonoids was selected based on the results of Shoskes et al. (15) . The patients enrolled were blinded to the type of treatment. A telephone follow up was then conducted 10 days after the treatment to ensure the correct compliance, whilst an outpatients follow up was carried out 30 days after the treatment consisting in a new set of questionnaires plus a urological examination and repeat microbiology cultures.
Inclusion/exclusion criteria Inclusion criteria for the enrolment were defined as follows: the presence of persistent pelvic pain for at least 3 months, in the 6 months preceding the study according to the EAU guidelines; NIH-CPSI pain score greater than 7 and a negative Meares-Stamey test (14) . Exclusion criteria were defined as follows: age less than 18 years old and more than 65 years old; anatomical abnormalities of the urinary tract system; additional urologic diseases; post-void residual urine volume (PVR) > 50 cc; known allergy to the active substance; patients who had recently undergone (< 4 weeks) oral or parenteral antibiotics treatment or who were using prophylactic antibiotic treatment (< 4 weeks); positivity to Chlamydia Trachomatis test, Ureaplasma Urealyticum, Neisseria Gonorrhoeae, Herpes Virus (HSV 1/2) and Human Papillomavirus (HPV).
Patients were randomized into two arms: one had flower pollen extract, two tablets in a single daily dose for four weeks in line with the previous study of Cai et al. The NIH-CPSI was used to determine the effectiveness of clinical therapy (18) . In particular, the expected mean difference for NIH-CPSI was chosen as the primary endpoint. All the specimen were collected during the urological examination and brought to the laboratory under refrigerated conditions, for cultures, DNA extraction and polymerase chain reaction for Chlamydia Trachomatis, Neisseria Gonorrhoeae, HSV 1/2, and HPV detection.
In addition all the subjects included in the study underwent rectal examination, transrectal ultrasonography, urine and semen cultures, colonies count, and antibiogram if needed (Figure 1 ).
Statistical analysis
The main statistical analysis was performed on the patient population "Intent-To-Treat", corresponding to all the randomized patients described in the CONSORT diagram ( Figure 1 ), a flowchart including the patients evaluated, randomized, analysed and excluded (for any reason). The baseline patient characteristics are reported as mean, standard deviation (SD), median, inter-quartile range (IQR), frequency, or relative percentage, depending on the type of variable distribution. For the baseline comparison (T0) in the two arms of the study we utilized the T-test for the independent variables and the comparisons of mean values. The chi-square was instead used for the comparison of proportions. The comparison of the mean values of the NIH-CPSI index between baseline (T0) and at 30 days (T1) was done using paired T-test. All the tests were two-tailed and the statistical significant value was determined to be 0.05. The sample size was calculated from a starting average waiting time of the variation of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) of 13 and a mean observed difference of 11 (SD ± 2.2) ( Table 1 ).
RESULTS
Of the 68 patients presented at our institution with prostatic like symptoms during the study time, 54 were enrolled and randomized. Of the 14 patients excluded, 7 refused the enrolment, 5 were on antibiotic treatment, and 2 reported known allergy to the active substance. The pre-intervention questionnaires had the following scores: NIH-CPSI 25.81 ± 1.61; IPSS 8.39 ± 1.74; QoL 0.55 ± 0.1 (Table 2) . Table 3 summarizes the clinical characteristics and the enrolment data of the samples taken by arm. There was a statistically significant difference in the duration of the symptoms pre-treatment, and a positive trend in the QoL. There were no other statistically significant differences. At one month follow up the observed results between patients that had taken the flower pollen extract were as follows: NIH-CPSI 12.22 ± 1.84, IPSS 7.3 ± 1.54, QoL 0.66 ± 0.1. Whereas the results for patients that had taken quercetin at the same interval were: NIH-CPSI 14.85 ± 1.85, IPSS 7.67 ± 1.27, QoL 0.59 ± 0.1 ( Table 4) . The improvement of the symptoms after taking flower pollen extract was statistically significant as compared to them taking quercetin (p = < 0.0001). The QoL score was also statistically superior in those taking flower pollen extract (p = 0.003). On the other hand, the IPSS score was similar among the two groups (p = 0.39). At the follow up all patients had a negative Meares-Stamey test, and showed similar laboratory values, as compared to the initial parameters. No adverse reactions have been reported from the treatment in either arms. The expected value (∆ NIH-CPSI), depicted in Chart I and II, obtained by evaluating the expected mean difference for the two arms of the NIH-CPSI pre and post treatment, was of 13.4444 ± 2.55 for the flower pollen extract , and of 11.11 ± 2.69 for the quercetin, being statistically significant (p = 0.0019) (Figure 1 ).
DISCUSSION
The main result of this study is the efficacy of the flower pollen extract in improving the quality of life and Table 1 . Calculation of the sample size. reduce pain in patients with CP/CPPS in a statistically significant way compared to the bioflavonoids complex with quercetin. This therapeutic improvement holds true for both the type IIIa and IIIb CP/CPPS patients. Those results are in line with the current literature showing the reduction of pain after 30 days of use of flower pollen extract compared to quercetin (10). This effect is probably secondary to the association between the pollen extract and the vitamins B6 and B12, which enhances the protective effects of the pollen extract on the nerves. In fact, as demonstrated in animal experiments, the vitamin B complex (including B1, B6, and B12) has analgesic effects in acute and chronic pain secondary to electrical and thermal stimulation, primary and post diabetic neuronal damage (20, 21) . Several studies have demonstrated that certain vitamin B, B6 and B12 in particular, are capable of protecting the neurons from specific lesions (22, 23) . Vitamin B1, B6, and B12 are effective in the treatment of painful syndromes such has lumbago, sciatic nerve neuralgia, trigeminal neuralgia, and the chronic pain associated with diabetic polyneuropathy (24) . In contrast to previous studies, our results show that there was no difference in either treatment arms between patient with non-inflammatory CP/CPPS and inflammatory CP/CPPS. Both the flower pollen extract and the quercetin were well tolerated for the entire duration of the protocol. The limitations of this study are the small number of patients enrolled, a short follow up period, and the selected nature of the patients enrolled. Furthermore, this was not set up as a double blind study.
In the absence of a therapeutic efficacy of the "conventional" medications, the therapeutic options with nutritional supplements are a valid alternative. In deciding the therapeutic intervention it is necessary to choose the active principle that determines an improvement of the QoL, the reduction of pain, with high safety levels.
CONCLUSIONS
Considering the above mentioned limitations, the flower pollen extract determined a significant improvement of the symptoms (pain, and quality of life) in the patients with CP/CPPS. A statistically significant difference was also noted in the expected value of the National Institute of Health Chronic Prostatitis Symptom Index (∆ NIH-CPSI) in the flower pollen extract group as compared to the Bioflavonoids complex with quercetin, without side effects. Table 3 . Clinical characteristics and enrollment data of the samples taken by arm. 
